Skip to main content
SpringerLink
Log in

Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)

Japanese Journal of Radiology volume 41, pages 777–786 (2023)Cite this article

Abstract

Purpose

To explore the prognostic value of the distance between the two lesions that were farthest apart (Dmax) on baseline 18F-FDG PET/CT in peripheral T lymphoma (PTCL) and establish a new prognostic model for predicting the survival outcomes of patients with PTCL.

Methods

In this study, a retrospective analysis of 95 patients with PTCL who underwent baseline 18F-FDG PET/CT was performed to assess the predictive value of Dmax. The total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), standardized uptake value (SUV), and Dmax were calculated with LIFEx software. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. The prognostic model was developed based on the results of the multivariate analysis. The time-dependent area under the ROC curve (tdAUC), calibration curves, Harrell C-index, and decision curve analysis (DCA) were used to assess the model.

Results

Patients were followed up for a median of 17.0 months. Multivariate analysis showed that bone marrow biopsy (BMB) and Dmax were independent predictors of PFS (HR: 1.889, P = 0.039; HR: 1.965, P = 0.047) and OS (HR: 1.923, P = 0.031; HR: 1.982, P = 0.034). The model consisting of Dmax, TMTV, and BMB had substantial prognostic value for survival outcomes of PTCL and could successfully identify four groups of patients with significantly different prognoses (χ2 = 13.731, P = 0.003 for PFS; χ2 = 11.841, P = 0.008 for OS). The tdAUC, C-index, calibration curves, and DCA supported that the model was superior to the prognostic index for T-cell lymphoma (PIT) and International Prognostic Index (IPI) scores.

Conclusion

BMB and Dmax were independent predictors of PTCL in our study. Moreover, a prognostic model based on the Dmax, TMTV, and BMB could be useful for predicting the survival outcomes of patients with PTCL.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Agostinelli C, Piccaluga PP, Went P, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 2008;61(11):1160–7. https://doi.org/10.1136/jcp.2008.055335.

    Article  CAS  PubMed  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D. International T-Cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/JCO.2008.16.4558.

    Article  PubMed  Google Scholar 

  3. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7. https://doi.org/10.1182/blood-2014-04-573089.

    Article  CAS  PubMed  Google Scholar 

  4. d’Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108–15. https://doi.org/10.1093/annonc/mdv201.

    Article  PubMed  Google Scholar 

  5. Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636–44. https://doi.org/10.1182/blood-2013-12-516245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397–404. https://doi.org/10.1093/annonc/mdq359.

    Article  PubMed  Google Scholar 

  7. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Aggressives). Ann Oncol. 1990;1(1):45–50. https://doi.org/10.1093/oxfordjournals.annonc.a057673.

    Article  CAS  PubMed  Google Scholar 

  8. Foss F. Hematology: relapsed and refractory PTCL–into the therapeutic abyss. Nat Rev Clin Oncol. 2011;8(6):321–2. https://doi.org/10.1038/nrclinonc.2011.51.

    Article  CAS  PubMed  Google Scholar 

  9. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94. https://doi.org/10.1056/NEJM199309303291402.

    Article  Google Scholar 

  10. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42. https://doi.org/10.1182/blood-2013-09-524108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9. https://doi.org/10.1182/blood-2003-09-3080.

    Article  CAS  PubMed  Google Scholar 

  12. Nakaya A, Fujita S, Satake A, et al. Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma. Leuk Res Rep. 2016;6:24–6. https://doi.org/10.1016/j.lrr.2016.06.003.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;106:55–63. https://doi.org/10.1016/j.critrevonc.2016.07.003.

    Article  PubMed  Google Scholar 

  14. Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896–903. https://doi.org/10.1200/JCO.2009.26.5942.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Trans. 2009;15(2):242–8. https://doi.org/10.1016/j.bbmt.2008.11.026.

    Article  Google Scholar 

  16. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109(3):905–9. https://doi.org/10.1182/blood-2006-04-019901.

    Article  CAS  PubMed  Google Scholar 

  17. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol. 2010;21(1):126–32. https://doi.org/10.1093/annonc/mdp271.

    Article  CAS  PubMed  Google Scholar 

  18. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. https://doi.org/10.1200/JCO.2013.53.5229. (published correction appears in J Clin Oncol 2016 Jul 20;34(21):2562).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhang Y, Wang G, Zhao X, et al. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). BMC Med Imaging. 2021;21(1):145. https://doi.org/10.1186/s12880-021-00674-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719–24. https://doi.org/10.1093/annonc/mdw011.

    Article  CAS  PubMed  Google Scholar 

  21. Cottereau AS, Meignan M, Nioche C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol. 2021;32(3):404–11. https://doi.org/10.1016/j.annonc.2020.11.019.

    Article  PubMed  Google Scholar 

  22. Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40–5. https://doi.org/10.2967/jnumed.119.229450.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49(3):932–42. https://doi.org/10.1007/s00259-021-05480-3.

    Article  PubMed  Google Scholar 

  24. Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study. Hematol Oncol. 2022;40(4):645–57. https://doi.org/10.1002/hon.3025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhou Y, Zhang X, Qin H, et al. Prognostic values of baseline 18F-FDG PET/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020. https://doi.org/10.1155/2020/9746716.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Jiang C, Teng Y, Chen J, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). EJNMMI Res. 2020;10(1):110. https://doi.org/10.1186/s13550-020-00698-y.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. https://doi.org/10.1007/s00259-009-1297-4.

    Article  PubMed  Google Scholar 

  28. Feeney J, Horwitz S, Gönen M, Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol. 2010;195(2):333–40. https://doi.org/10.2214/AJR.09.3665.

    Article  PubMed  Google Scholar 

  29. Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587–600. https://doi.org/10.18632/oncotarget.20447.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Liang JH, Zhang YP, Xia J, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019;51(4):1479–87. https://doi.org/10.4143/crt.2018.649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yi S, An G, Qi J, et al. The significance of bone marrow involvement in aggressive lymphomas: a retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China. Acta Haematol. 2010;124(4):239–44. https://doi.org/10.1159/000321544.

    Article  PubMed  Google Scholar 

  32. Koh Y, Lee JM, Woo GU, et al. FDG PET for evaluation of bone marrow status in T-cell lymphoma. Clin Nucl Med. 2019;44(1):4–10. https://doi.org/10.1097/RLU.0000000000002320.

    Article  PubMed  Google Scholar 

  33. Abe Y, Kitadate A, Usui Y, et al. Diagnostic and prognostic value of using 18F-FDG PET/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma. Clin Nucl Med. 2019;44(5):e336–41. https://doi.org/10.1097/RLU.0000000000002516.

    Article  PubMed  Google Scholar 

  34. Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Nucl Med Commun. 2016;37(12):1267–72. https://doi.org/10.1097/MNM.0000000000000579.

    Article  CAS  PubMed  Google Scholar 

  35. Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1–5. https://doi.org/10.1016/j.amjoto.2017.10.009.

    Article  PubMed  Google Scholar 

  36. Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28(2):57–61. https://doi.org/10.1002/hon.905.

    Article  PubMed  Google Scholar 

  37. Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195–202. https://doi.org/10.1002/cncr.27855.

    Article  CAS  PubMed  Google Scholar 

  38. Yang J, Zhu S, Pang F, et al. Functional parameters of 18F-FDG PET/CT in patients with primary testicular diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2018. https://doi.org/10.1155/2018/8659826.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(4):773–80. https://doi.org/10.3109/10428194.2013.831848.

    Article  CAS  PubMed  Google Scholar 

  40. Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(9):1735–43. https://doi.org/10.1007/s00259-014-2783-x.

    Article  PubMed  Google Scholar 

  41. Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19. https://doi.org/10.1007/s00259-016-3315-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large b-cell lymphoma. Clin Cancer Res. 2016;22(15):3801–9. https://doi.org/10.1158/1078-0432.CCR-15-2825.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The research did not receive specific funding.

Author information

Author notes

  1. Yiting Xie and Yue Teng are co-first authors and they have contributed equally to the work.

Authors and Affiliations

  1. Nanjing Drum Tower Hospital, Clinical College of Jiangsu University, Nanjing, China

    Yiting Xie

  2. Department of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000, China

    Yue Teng & Chong Jiang

  3. Department of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

    Chongyang Ding

  4. Department of Radiology, Nanjing Drum Tower Hospital, Clinical College of Jiangsu University, Nanjing, China

    Zhengyang Zhou

Authors
  1. Yiting Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chongyang Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhengyang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chongyang Ding or Zhengyang Zhou.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This study was conducted in accordance with the ethical standards set out in the 1964 Declaration of Helsinki and all subsequent revisions.

Consent to participate

Approval was obtained from the institution review boards, and all of the subjects signed a written consent form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, Y., Teng, Y., Jiang, C. et al. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL). Jpn J Radiol 41, 777–786 (2023). https://doi.org/10.1007/s11604-023-01398-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-023-01398-y

Keywords

Search

Navigation